A Clinical Grade Sequencing-Based Assay for Mutation Testing: Report of a Large Series of Myeloid Neoplasms

Diagnostic testing for CEBPA mutations is the standard of care for cytogenetically normal acute myeloid leukemia. Widespread implementation of this testing is hampered by technical challenges associated with the GC content of the gene, the variability of the mutations, and the complexity of the sequence analysis and variant interpretation. We developed a robust Sanger-sequencing test to detect CEBPA mutations in diagnostic acute myeloid leukemia specimens. Our experience with testing 2393 cases of suspected myeloid neoplasms is presented.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular Article Source Type: research

Related Links:

CONCLUSIONS: Survivors of childhood cancer remain at increased risk of a second primary cancer well into adulthood. As the late effects of cancer treatment probably contribute to this risk, treatments need to be refined and their toxicity reduced, without reducing their benefit for survival. PMID: 31743457 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Conclusions: The 5-year OS of patients with stage III NSCLC treated with CRT was in keeping with survival figures reported from prospective clinical trials. There is, however, significant morbidity associated with long-term survival and this should be taken into account when making informed treatment decisions. PMID: 31737309 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
During the past decades, autologous hematopoietic cell transplantation (HCT) has been widely used as consolidation treatment in patients with acute myeloid leukemia (AML) in first or second complete remission (CR) [1 –11]. Over time, donors for allogeneic stem cell transplantation have become available and allogeneic HCT appears to have in part replaced autologous HCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
awa Miura FLT3-ITD is the most frequent tyrosine kinase mutation in acute myeloid leukemia (AML) associated with poor prognosis. We previously found that FLT3-ITD activates the mTORC1/S6K/4EBP1 pathway cooperatively through the STAT5/PIM and PI3K/AKT pathways to promote proliferation and survival by enhancing the eIF4F complex formation required for cap-dependent translation. Here, we show that, in contrast to BCR/ABL causing Ph-positive leukemias, FLT3-ITD distinctively activates the serine/threonine kinases RSK1/2 through activation of the MEK/ERK pathway and PDK1 to transduce signals required for FLT3-ITD-depende...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara Sponsor:   Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara Sponsor:   Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Intervention:   Drug: rhTPO Sponsor:   Huihan Wang Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara Sponsor:   Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Intervention:   Drug: rhTPO Sponsor:   Huihan Wang Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara Sponsor:   Celyad (formerly named Cardio3 BioSciences) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Genetics | Leukemia | Pathology